肿瘤细胞治疗研究
英文原题：Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients
Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients
⚠ 该试验的登记信息已有 21 个月未更新， 页面上显示的「进行中（不再招募）」可能已经失效。联系研究中心之前，建议先到 ClinicalTrials.gov 核对登记原文的最新状态与联系方式。
这是一项分期未标注的注册临床试验，评估细胞治疗用于弥漫大 B 细胞淋巴瘤的安全性、可行性及初步疗效。当前状态：进行中（不再招募）。计划入组 15 例。试验地点：欧洲 · 博洛尼亚（共 1 个中心）。登记号：NCT06760936。
不限性别 · ≥ 18 Years
入选标准： 1. 复发或难治性弥漫大 B 细胞淋巴瘤（DLBCL），在 allo-HSCT 或 CAR-T 前最后一线治疗接受 pixantrone，或治疗计划为先用 pixantrone 再接受 allo-HSCT 或 CAR-T。 2. 入组时年龄≥18岁。 3. 如适用，提供书面知情同意。 排除标准：无。
Inclusion Criteria: 1. Patients with relapsed or refractory DLBCL who received pixantrone as last line of therapy prior to allo-HSCT or CAR-T cell therapy or patient's whose therapeutic program is treatment with pixantrone prior to allo-HSCT or CAR-T cell therapy. 2. Age ≥ 18 years at enrolment. 3. Written informed consent (if applicable). Exclusion Criteria: 1\) none
以上为辅助阅读译文。是否适合入组须由主治医生判断，最终以登记平台与研究者确认为准。
主要终点：Effectiveness of pixantrone as bridging therapy to allo-HSCT or CAR-T therapy. · Number of patients able to proceed to transplant/CAR-T · through study completion, an average of 2 years
次要终点：Treatment duration；patient's response to the treatment with pixantrone；type of adverse events (AE)；Assessment of OS；causes of discontinuation；Incidence of adverse events (AE)；Incidence serious adverse events (SAE)；type of serious adverse events (SAE)
这是一项回顾性/前瞻性、多中心观察性研究，旨在描述 pixantrone 作为异基因造血干细胞移植（allo-HSCT）或 CAR-T 治疗桥接方案的效果。
Retrospective/prospective observational multicentric study aimed at describing the effectiveness of pixantrone as bridging therapy to allo-HSCT or CAR-T therapy
MEMBER ACCOUNT
登录成功会直接打开下一页。
